Seeking Alpha

More from the ASCO Oncology conference: Array BioPharma (ARRY) says its MEK162 selective...

More from the ASCO Oncology conference: Array BioPharma (ARRY) says its MEK162 selective inhibitor shows promising clinical activity in Phase ll trial in patients with NRAS mutated melanoma. Shares +2.5% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector